Another case report links sodium-glucose co-transporter 2 (SGLT2) inhibitors like Invokana to diabetic ketoacidosis, a severe and potentially fatal condition wherein the body produces too many blood acids. The article, published in the journal Practical Diabetes, presents the case of a 58-year-old woman who suffered severe diabetic ketoacidosis after her twice-daily insulin regimen was replaced by dapagliflozin.
SGLT2 inhibitors, the new class of type 2 diabetes medication introduce in 2013, were first linked to ...
continue reading...
According to a Medscape article, the results of the first-ever Phase 2 study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in type 1 diabetes patients have been reported—and they 
The U.S. Food and Drug Administration (FDA) has released a safety alert for Invokana and Invokamet, two drugs in a new line of diabetes medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors. The agency has strengthened warnings about the increased risk of bone fractures associated with the drugs and added information about loss of bone mineral density. Both Invokana (canaglifolozin) and Invokamet (canagliflozin and metformin) use Janssen Pharmaceutical’s SGLT2 inhibitor ...
A recent Reuters article reports that Eli Lilly & Co. and Boehringer Ingelheim have received 
While sodium-glucose cotransporter-2 (SGLT2) inhibitors draw praise for their weight-loss and blood pressure reduction benefits, medical experts continue to puzzle over their more immediate metabolic and immune system effects. Specifically, researchers are worried about their possible link to diabetic ketoacidosis, a potentially fatal condition caused by excess blood acids, or ketones. In an article published by the Journal of Diabetes Investigation, two Japanese researchers provide a possible explanation for how 
